Skip to main content

Day: May 31, 2022

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief Financial Officer. “Matt’s deep experience in cell therapy product development was an important consideration in Brooklyn’s choice to license...

Continue reading

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022

GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82nd American Diabetes Association (ADA) Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022. Dr. Klein will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows:Title: Pemvidutide (ALT-801), a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss...

Continue reading

Jushi Holdings Inc. Announces Participation in Upcoming Conference and Event in June 2022

BOCA RATON, Fla., May 31, 2022 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that Jushi’s management will participate in the following upcoming conferences and events:Jefferies Cannabis Summit is being held on Thursday, June 2, 2022. Ed Kremer, Chief Financial Officer, and Michael Perlman, EVP of Investor Relations, will be hosting a series of one-on-one investor meetings throughout the event located at the InterContinental New York Barclay at 111 E 48th Street, New York, New York. For more information, please contact your Jefferies representative.Security Industry Association’s Vertical Insights Symposium Series: Cannabis Security is being held on Tuesday, June 7, 2022. Jennifer Duey, VP of Physical Security, is...

Continue reading

PyroGenesis Announces Completed Production of Additional 100kg Titanium Powder Order for 3D Printing; Readies Move to Higher Output Phase

MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), a high-tech company (hereinafter referred to as the “Company” or “PyroGenesis”), that designs, develops, manufactures and commercializes advanced plasma processes, high quality plasma atomized metal powder for 3D printing, and sustainable solutions which are geared to reduce greenhouse gases (GHG), is pleased to announce that the Company has received, and completed, another commercial order for its plasma atomized titanium powders for 3D printing. “This latest order, for 100kg, represents the second consecutive commercial batch of metal powders produced using the Company’s NexGen™ plasma atomization system, at our state-of-the-art production facility in Montreal, in as many weeks,” said Mr. Massimo Dattilo,...

Continue reading

Achiko AG Publication of Annual Report and Annual Financial Statements 2021 to Occur by June 6, 2022

ZURICH, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on June 6, 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing, and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed...

Continue reading

Marathon Gold Makes Engineering and Construction Management Appointments for Valentine Gold Project

TORONTO, May 31, 2022 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) is pleased to provide an update on project execution planning at the Valentine Gold Project located in central Newfoundland (the “Project”). Marathon announces that is has signed a Letter of Intent with SNC-Lavalin to complete detailed engineering for the Project’s mill and major facilities, and develop related equipment and construction packages. SNC-Lavalin is a fully integrated professional services and project management company with offices around the world that has particular experience in the engineering and delivery of mineral processing projects. Detailed engineering for the Project’s Tailings Management Facility continues under Golder Associates Ltd., Stantec Consulting Ltd. will complete the site water management...

Continue reading

AC Immune to Present at the 2022 Jefferies Healthcare Conference

LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis hotel in New York, NY from June 8-10, 2022. During the fireside chat, AC Immune’s CEO Andrea Pfeifer, will provide an overview of the progress being made across the Company’s development pipeline, which includes both cutting edge-diagnostics and highly selective therapeutics that are collectively designed to shift the neurodegenerative disease treatment paradigm towards earlier diagnosis and disease prevention. Dr. Pfeifer will also outline the...

Continue reading

Superior Group of Companies Announces Michael Koempel as New Chief Financial Officer

Andrew D. Demott, Jr. to Remain as Chief Operating Officer and Director; Announces Retirement as an Employee Effective in 2023 SEMINOLE, Fla., May 31, 2022 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC), is pleased to announce that the Board of Directors of the Company has appointed Michael Koempel to the role of Chief Financial Officer (CFO) of the Company, effective May 31, 2022.   Koempel, with more than 30 years of broad financial experience, has an impressive record of building and scaling high growth apparel and retail brands. Most recently, Koempel was chief operating officer of IT’SUGAR®, one of the largest specialty candy retailers in the U.S. Prior to that, Koempel served as chief operating officer of Victoria’s Secret Lingerie, a multi-billion dollar e-commerce and store-based retailer specializing...

Continue reading

Lilium Achieves Main Wing Transition

Lilium achieves main wing transition Lilium achieves main wing transitionMUNICH, Germany, May 31, 2022 (GLOBE NEWSWIRE) — (Lilium N.V. (NASDAQ: LILM) (“Lilium”), developer of the first all-electric vertical take-off and landing (“eVTOL”) jet, today announced that its technology demonstrator Phoenix 2 has achieved main wing transition. This means it is the first ever full-size electric jet aircraft to transition from hover to wing-borne flight. This is a landmark moment for Lilium and for electric aviation as a whole. From a flight physics perspective, completing transition means the airflow going over the flaps attaches and becomes smooth, allowing the lift to be generated by the wing (as in conventional fixed wing aircraft), rather than by the engines (which is the case during the hovering phase). Phoenix 2 has now achieved...

Continue reading

MamaMancini’s Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Q4 2022 Revenues Increase 38.5% to Record $13.9 Million EAST RUTHERFORD, NJ, May 31, 2022 (GLOBE NEWSWIRE) — MamaMancini’s Holdings, Inc. (NASDAQ: MMMB), a marketer and distributor of specialty pre-prepared all-natural foods, has reported its financial results for the fourth quarter and fiscal year ended January 31, 2022. Financial Summary:    Three Months Ended Jan. 31,    Fiscal Year Ended Jan. 31,  $ in millions   2022     2021   % Increase     2022     2021   % Increase  Revenues   $ 13.9     $ 10.0   38.5 %   $ 47.1     $ 40.8   15.4 %Gross Profit   $ 2.4     $ 3.3   -26.8 %   $ 11.9     $ 12.7   -6.3 %Operating Expenses   $ 3.8     $ 2.4   57.1 %   $ 11.8     $ 9.3   26.9 %Net Income (Loss)   ($ 1.3 )   $ 1.7   –     ($ 0.4 )   $ 4.1   –  Earnings per Share (Diluted)   ($ 0.04 )   $ 0.05   –     ($ 0.01 )   $ 0.12   –  Key...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.